These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 28870792)

  • 1. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
    Schwer AL; Damek DM; Kavanagh BD; Gaspar LE; Lillehei K; Stuhr K; Chen C
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):993-1001. PubMed ID: 17967517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma.
    Chen ATC; Serante AR; Ayres AS; Tonaki JO; Moreno RA; Shih H; Gattás GS; Lopez RVM; Dos Santos de Jesus GR; de Carvalho IT; Marotta RC; Marta GN; Feher O; Neto HS; Ribeiro ISN; Vasconcelos KGMDC; Figueiredo EG; Weltman E
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1122-1132. PubMed ID: 38232937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
    J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.
    Hudes RS; Corn BW; Werner-Wasik M; Andrews D; Rosenstock J; Thoron L; Downes B; Curran WJ
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):293-8. PubMed ID: 10030252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined stereotactic split-course fractionated gamma knife radiosurgery and conventional radiation therapy for unfavorable gliomas: a phase I study.
    Regine WF; Patchell RA; Strottmann JM; Meigooni A; Sanders M; Young B
    J Neurosurg; 2000 Dec; 93 Suppl 3():37-41. PubMed ID: 11143260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
    Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent Brain Metastasis with Previously High-Dose Irradiation.
    Guan Y; Wang C; Zhu H; Li J; Xu W; Sun L; Pan L; Dai J; Wang Y; Wang E; Wang X
    World Neurosurg; 2020 Jan; 133():e252-e258. PubMed ID: 31505283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
    Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.
    Minniti G; Agolli L; Falco T; Scaringi C; Lanzetta G; Caporello P; Osti MF; Esposito V; Enrici RM
    J Neurooncol; 2015 May; 122(3):559-66. PubMed ID: 25702193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
    Lee J; Ahn SS; Chang JH; Suh CO
    Yonsei Med J; 2018 Mar; 59(2):194-201. PubMed ID: 29436186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary report of a phase I study of combined fractionated stereotactic radiosurgery and conventional external beam radiation therapy for unfavorable gliomas.
    Regine WF; Patchell RA; Strottmann JM; Meigooni A; Sanders M; Young AB
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):421-6. PubMed ID: 10974456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
    Magnuson W; Ian Robins H; Mohindra P; Howard S
    J Neurooncol; 2014 Mar; 117(1):133-9. PubMed ID: 24469853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
    Shi W; Palmer JD; Werner-Wasik M; Andrews DW; Evans JJ; Glass J; Kim L; Bar-Ad V; Judy K; Farrell C; Simone N; Liu H; Dicker AP; Lawrence YR
    J Neurooncol; 2016 May; 127(3):535-9. PubMed ID: 26821711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.